ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 142 papers, 9 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 9 pooled it
74.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 9 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates.Frontiers in immunology · 2026Pooled it
- SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis.Breast cancer research and treatment · 2025Pooled it
- Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.Current oncology (Toronto, Ont.) · 2025Guideline
- The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials.Breast (Edinburgh, Scotland) · 2024Pooled it
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.ESMO open · 2024Guideline
- Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Neoadjuvant vs. Adjuvant Chemotherapy for Luminal B Breast Cancer: A Systematic Review and Meta-Analysis - Where is the Evidence?Cancer control : journal of the Moffitt Cancer CenterPooled it
- Trial
- Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.Breast cancer research : BCR · 2026Trial
- Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.Nature communications · 2026Trial
- Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Trial
- Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.ESMO open · 2025Trial
- Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitudeCancer biology & therapy · 2026Article
- Evaluating total tumor load (TTL) to predict metastasis in four or more axillary lymph nodes in HR +/HER2- breast cancer patients: the TULIP4N + study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer.Science advances · 2026Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
23 authors at 19 institutions in 13 countries.
Priya RastogiUPMC Hillman Cancer Center and NSABP Foundation, Pittsburgh, PA.ORCID 0000-0002-6179-6407
Joyce O'ShaughnessyBaylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.
Miguel MartinHospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain.ORCID 0000-0001-9237-3231
Frances BoyleSydney Medical School, University of Sydney, Sydney, Australia.ORCID 0000-0003-3798-1570
Javier CortesInternational Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain.ORCID 0000-0001-7623-1583
Hope S RugoUSCF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.ORCID 0000-0001-6710-4814
Matthew P GoetzMayo Clinic, Rochester, MN.ORCID 0000-0002-4383-270X
Erika P HamiltonSarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.ORCID 0000-0002-1911-0336
Chiun-Sheng HuangNational Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-6557-211X
Elzbieta SenkusMedical University of Gdańsk, Gdańsk, Poland.
Alexey TryakinN.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation.ORCID 0000-0003-2245-214X
Irfan CicinIstinye University, Istanbul, Turkey.ORCID 0000-0002-7584-3868
Laura TestaD'Or Institute for Research and Education (IDOR), São Paulo, Brazil.ORCID 0000-0001-6080-7429
Patrick NevenUniversity Hospitals Leuven, Louvain, Belgium.ORCID 0000-0002-1434-9460
Jens HuoberKantonsspital St Gallen, St Gallen, Switzerland.ORCID 0000-0002-8618-1820
Zhimin ShaoFudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0002-4503-148X
Ran WeiEli Lilly and Company, Indianapolis, IN.
Valérie AndréEli Lilly and Company, Indianapolis, IN.
Maria MunozEli Lilly and Company, Indianapolis, IN.
Belen San AntonioEli Lilly and Company, Indianapolis, IN.
Ashwin ShahirEli Lilly and Company, Indianapolis, IN.
Nadia HarbeckComprehensive Cancer Centre München, LMU University Hospital, Munich, Germany.ORCID 0000-0002-9744-7372
Stephen JohnstonThe Royal Marsden NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-9072-2749
Eli Lilly (United States) · USD’Or Institute for Research and Education · BRFudan University Shanghai Cancer Center · CNGdańsk Medical University · PLHospital General Universitario Gregorio Marañón · ESHospital Quirónsalud Barcelona · ESIstinye University · TRKantonsspital St. Gallen · CHKU Leuven · BELMU Klinikum · DEMayo Clinic in Arizona · USNational Taiwan University Hospital · TWRoyal Marsden NHS Foundation Trust · GBRussian Cancer Research Center NN Blokhin · RUSarah Cannon · USTexas Oncology · USThe University of Sydney · AUUniversity of California, San Francisco · USUPMC Hillman Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AminopyridinesBenzimidazolesBreast NeoplasmsAdjuvants, ImmunologicAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoplasm Recurrence, LocalabemaciclibAdjuvants, ImmunologicAminopyridinesBenzimidazolesERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.